About
David Mott led New Enterprise Associates' healthcare investing as a general partner after serving as chief executive of biotech company MedImmune, which AstraZeneca acquired for $15.6 billion.
Deals · 1
TesaroBoard seat
via New Enterprise Associates (NEA) · filed Apr 2016 · $50M raise
Attribution from SEC filings, press coverage, and firm rosters.